Free download. Book file PDF easily for everyone and every device. You can download and read online Leukemia: Recent Developments in Diagnosis and Therapy file PDF Book only if you are registered here. And also you can download or read online all Book PDF file that related with Leukemia: Recent Developments in Diagnosis and Therapy book. Happy reading Leukemia: Recent Developments in Diagnosis and Therapy Bookeveryone. Download file Free Book PDF Leukemia: Recent Developments in Diagnosis and Therapy at Complete PDF Library. This Book have some digital formats such us :paperbook, ebook, kindle, epub, fb2 and another formats. Here is The CompletePDF Book Library. It's free to register here to get Book file PDF Leukemia: Recent Developments in Diagnosis and Therapy Pocket Guide.

Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pedia Blood Cancer. Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Br J Cancer. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.

Molecular landscape and targeted therapy of acute myeloid leukemia

N Engl J Med. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. New malignancies following childhood cancer in the United States, — Int J Oncol. Download references. Food and Drug Administration.

Correspondence to Pragati G.

  1. Devils and Rebels: The Making of Hawthornes Damned Politics?
  2. Leukemia Treatment for Adults.
  3. Introduction.

Presentation: These data were presented in part at the Conference on Radiation and Health, in Chicago, Illinois, September 23—25, Reprints and Permissions. Advanced search. Skip to main content. Subjects Acute myeloid leukaemia Cancer epidemiology Chemotherapy. Access options Access options Subscribe to Journal Get full journal access for 1 year 1.

Rent or Buy article Get time limited or full article access on ReadCube. References 1. PubMed Google Scholar 4. PubMed Google Scholar 8. Google Scholar 9. Google Scholar CAS Google Scholar Blood ; : — Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol ; 4 : Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia ; 28 : — Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.

Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leuk Res ; 32 : — Yamada O, Kawauchi K. The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies. Constitutive Stat3, Tyr, and Ser phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin Blood ; 95 : — Clin Cancer Res ; 9 : — Leukemia ; 20 : — Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.


The revision of the World Health Organization WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood ; :. Results of intensive chemotherapy in patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer ; : — Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol ; 29 : — Rangert et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.

Am J Hematol ; 90 : — Estey EH. Acute myeloid leukemia: update on risk-stratification and management. Am J Hematol ; 89 : — Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol ; 30 : — Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.

Leuk Res ; 38 : — J Clin Oncol ; 24 : — Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res ; 35 : — Ann Lab Med ; 35 : — Mutant nucleophosmin NPM1 predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. Eur J Haematol ; 94 : — Prognostic significance of activating FLT3 mutations in younger adults 16 to 60 years with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol ; 93 : — Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Diversity of the juxtamembrane and TKD1 mutations exons in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer ; 51 : — A novel hierarchical prognostic model of AML solely based on molecular mutations. Leuk Res ; 37 : — Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

J Clin Oncol ; 33 : — Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. Anderson Cancer Center Study. J Clin Oncol ; 28 : — Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.

Eur J Haematol ; 91 : — Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant ; 48 : — Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leuk Res ; 40 : 1—9. High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of prospective clinical trials.

PLoS One ; 10 : e Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood ; : 26— Cytarabine dose for acute myeloid leukemia. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol ; 31 : — J Clin Oncol ; 7 : — Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Leukemia - Wikipedia

Anthracycline dose intensification in acute myeloid leukemia. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF flag regimen : a single center study. Leuk Lymphoma ; 40 : — High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol ; 3 : — Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.

J Clin Oncol ; 9 : — Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Leukemia ; 8 : 6— Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

JAMA ; : — Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer ; :. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways

Blood ; 88 : — Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol ; 32 : — Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Leukemia ; 29 :. Efficacy of allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: a meta-analysis of prospective studies.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst ; : — Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica ; 96 : 62— Leuk Lymphoma ; 51 : — A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia ; 24 : — Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk ; 11 : — Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets ; 19 : 37— Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia SORAML : a multicentre, phase 2, randomised controlled trial.

Lancet Oncol ; 16 : — Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant ; 20 : — Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk ; 15 : — High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

Leukemia ; 26 : — Blood ; : 54— A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk ; 15 : —, e2.

  • Recent advances in the understanding and treatment of acute myeloid leukemia.
  • Pepe Le Moko (BFI Film Classics).
  • Understanding HIV AIDS Mgmt., Care - Pandemic Apprs. in the 21st Cent.?
  • The Initial Psychotherapy Interview: A Gay Man Seeks Treatment.
  • Balancing Exploitation and Exploration: Organizational Antecedents and Performance Effects of Innovation Strategies;
  • Acknowledgments?
  • Revenge of the Horned Bunnies (Dragonbreath, Book 6).
  • Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood ; : ASH abstract Crenolanib is a selective type I pan-FLT3 inhibitor. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.

    • Shop now and earn 2 points per $1.
    • Ordinary People as Mass Murderers: Perpetrators in Comparative Perspectives.
    • 12 Smart Things to Do When the Booze and Drugs Are Gone.
    • Leukemia - Wikipedia;
    • Leukaemia and Myeloma: Essentials for Clinicians | OncologyPRO.
    • Abandoned and Forgotten: An Orphan Girls Tale of Survival During World War II;
    • A novel STAT3 inhibitor has potent activity in preclinical models of acute myeloid leukemia that incorporate the stromal environment. Cancer Res Treat ; 47 : — Blood Cancer J ; 3 : e Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

      Science ; : — San Diego, CA. Clinical safety and activity in a phase I trial of AG, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies. Eur J Cancer ; 50 : Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

      1. Introduction

      Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol ; 88 : — Leukemia ; 30 : — Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.

      Cancer Chemother Pharmacol ; 67 : — A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol ; 15 : — J Clin Oncol ; 34 : — J Pathol ; : 13— CDspecific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

      Leukemia ; 29 : — Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer ; 85 : — Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood ; 96 : — Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Download references. Correspondence to M Abdul-Hay. This work is licensed under a Creative Commons Attribution 4. Reprints and Permissions. Frontiers in Pharmacology Medicinal Research Reviews